New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
about
Computed Tomography and Ultrasounds for the Follow-up of Hepatocellular Carcinoma Ablation: What You Need to KnowRadiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysisFusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types.A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenibPreoperative lipiodol marking and its role on survival and complication rates of CT-guided cryoablation for small renal masses.Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?Imaging of hepatocellular carcinoma and image guided therapies - how we do it.Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.New concepts in embolotherapy of HCC.Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5.Dual-balloon infusion microcatheter for selective drug-eluting bead transarterial chemoembolization: initial feasibility study.Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis.MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement?
P2860
Q26767189-1E8BF9C8-DC55-4EA3-818F-8B61B75364D3Q34680081-6805CB2B-3C4F-4C12-BE32-F0B89219969CQ35781818-A904123C-7501-440A-9DE4-418A81126E9AQ36223538-A87BE26E-2B4D-45DB-9629-4CD29CD9A751Q36253173-262ACFBE-C1B3-4439-A784-4851DFBFE95CQ36416250-B5F5262D-A6A3-4C59-B544-41021FC5FC03Q36582635-65D69630-2AB3-4AEA-B49D-83CE7C41CB0BQ37680183-1E72D50E-27C9-4E6F-8947-49E8DD4FCB28Q38792625-23AE723F-5BA6-4F12-81CE-FB901202E9A9Q38904263-9872E211-EED7-4964-BA3C-3F43D0749D8CQ40333754-BC02ABE2-2463-4DB2-B7C4-7E8B2D42A414Q40444455-299854BC-8A2D-4E67-BC04-34429BA63F48Q41435420-F39E69FD-4A29-4932-AE2A-B7401CDFBBE8Q42208584-73610357-AE1C-47C2-A9BC-32DE76804534Q43242540-E1DA82AD-415E-4976-9644-76B8E923069DQ50218004-06DD9662-5392-4CF1-8D52-6251B01B03FEQ53033550-CF62625F-932D-47F7-882C-22676D584721Q53173190-DF7A2FF5-4214-49D7-8B14-14D09BCF721AQ53218066-36FDBBD5-27C5-4ADF-ADFB-92F63BEEF8A1Q55020735-247617C9-8821-49BA-9E95-9D5E88AF6605
P2860
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
@ast
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
@en
type
label
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
@ast
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
@en
prefLabel
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
@ast
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
@en
P1476
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
@en
P2093
Riccardo Lencioni
P304
P356
10.1158/1078-0432.CCR-12-3796
P407
P577
2013-02-04T00:00:00Z